Based on the MacroGenics Inc stock forecast from 5 analysts, the average analyst target price for MacroGenics Inc is USD 5.20 over the next 12 months. MacroGenics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of MacroGenics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, MacroGenics Inc’s stock price was USD 1.26. MacroGenics Inc’s stock price has changed by +14.55% over the past week, -43.24% over the past month and -92.56% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for MacroGenics Inc
No recent average analyst rating found for MacroGenics Inc
Company Overview MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. Read Less
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets che...Read More
Frequently Asked Questions About MacroGenics Inc (MGNX) Stock
Based on ratings from 5 analysts MacroGenics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on MGNX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for MGNX is USD 5.20 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 2.
MGNX stock's Price/Earning ratio is 10.43.
Our analysis grades MGNX stock's Price / Earning ratio at F. This means that MGNX stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MGNX may be a overvalued for its sector.
The last closing price of MGNX's stock was USD 1.26.
The most recent market capitalization for MGNX is USD 0.08B.
Based on targets from 5 analysts, the average taret price for MGNX is projected at USD 5.20 over the next 12 months.
This means that MGNX's stock price may go up by +312.70% over the next 12 months.
We can't find any ETFs which contains MacroGenics Inc's stock.
As per our most recent records MacroGenics Inc has 341 Employees.
MacroGenics Inc's registered address is 9704 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from MacroGenics Inc's website at https://www.macrogenics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About MacroGenics Inc (MGNX) Stock
Based on ratings from 5 analysts MacroGenics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on MGNX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for MGNX is USD 5.20 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 2.
MGNX stock's Price/Earning ratio is 10.43.
Our analysis grades MGNX stock's Price / Earning ratio at F. This means that MGNX stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MGNX may be a overvalued for its sector.
The last closing price of MGNX's stock was USD 1.26.
The most recent market capitalization for MGNX is USD 0.08B.
Based on targets from 5 analysts, the average taret price for MGNX is projected at USD 5.20 over the next 12 months.
This means that MGNX's stock price may go up by +312.70% over the next 12 months.
We can't find any ETFs which contains MacroGenics Inc's stock.
As per our most recent records MacroGenics Inc has 341 Employees.
MacroGenics Inc's registered address is 9704 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from MacroGenics Inc's website at https://www.macrogenics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MGNX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
